Shots: Teva was assessing laquinimod since 2007, globally the drug completed three P-III studies ALLEGRO, BRAVO and CONCERTO in rrMS, P-II study ARPEGGIO in primary progressive MS and single P-II LEGATO-HD trial in Huntington’s Disease(HD) The P-II LEGATO-HD trial in HD fails to meet 1EP@12 mos, additionally in Dec 2017, P-II POC study of laquinimod […]Read More
